2009 Drug Development Immunity 
pharmaphorum
MARCH 29, 2021
The way NICE reviews new medicines is about to go through its biggest change in years – but what do the proposals mean for the future of drug development in the UK? We have gone from making drugs for breast cancer to making drugs that are targeted to just specific types of breast cancer that express certain genetic markers.
European Pharmaceutical Review
DECEMBER 22, 2022
2 A bsAb can have clinical advantages over conventional monoclonal antibodies (mAbs) including targeting functionally interrelated checkpoint inhibitors, directing immune responders to cancer cells, enhancing specificity and decreasing off-target toxicity. 2017 Aug 1;28(8):2009-2012. Available at: doi.org/10.1016/j.ctrv.2021.102240.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaShots
FEBRUARY 21, 2023
Market Cap: $8.57M Founded Year: 2009 Total Employees: ~40 Headquarters: Oslo, Norway Stock Exchange: OSE Nordic Nanovector is a biotech company committed to developing and commercializing antibody-radionuclide conjugates to address significant unmet medical needs.
Pharmaceutical Technology
FEBRUARY 1, 2023
During the 2009–19 period, children in the US ages five years and younger accounted for 58, 000 annual RSV-related hospitalisations and 100–500 annual deaths. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind. GlobalData is the parent company of Pharmaceutical Technology.
Pharmaceutical Technology
AUGUST 26, 2008
In December 2006 it acquired MacroMed Inc, a privately owned speciality drug development and manufacturing company based in the US, for its lead product OncoGel™ for the treatment of oesophageal and brain cancers. The blood pressure results are expected in the first half of 2009.
Expert insights. Personalized for you.
93 
Let's personalize your content